$30.5m market cap
$0.27 last close
Sunesis Pharmaceuticals focuses on oncology. Its lead asset is SNS-510, a PDK1 inhibitor in preclinical studies for a range of solid and hematologic tumors. It recently discontinued the vecabrutinib development program. It has also developed pan-Raf inhibitor TAK-580, currently licensed to DOT Therapeutics.
Investment summary
Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead program is SNS-510, a novel PDK1 inhibitor. The company plans to file an IND for the drug and begin clinical trials in 2020. It recently discontinued its vecabrutinib program after seeing limited activity in Phase I.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.2 | (25.7) | (26.6) | (74.80) | N/A | N/A |
| 2019A | 2.1 | (23.3) | (23.3) | (26.78) | N/A | N/A |
| 2020E | 0.1 | (20.0) | (19.9) | (13.60) | N/A | N/A |
| 2021E | 0.0 | (18.4) | (19.9) | (10.52) | N/A | N/A |
Industry outlook
Sunesis is an oncology company with an early-stage asset with a validated target for the treatment of B-cell malignancies.
Last updated on 01/09/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 23.9 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Dayton Misfeldt | Interim CEO |
